| Source publication date | (update date shown as 2026-09-16) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men and women |
| Source | Acibadem International |
| URL | acibademinternational.com/blog/testosterone-pellets-vs-gels-vs-injections-how-the-delivery-method-changes-levels-and-risks (opens in a new tab) |
Specific Claim Evaluated
Injections produce the largest rise in hematocrit and gels the smallest; TRAVERSE found no increase in heart attack, stroke or cardiovascular death with testosterone gel but did not study pellets or women, and the 2019 consensus recommends against pellets in women.
Primary Research Supporting or Contradicting the Claim
TRAVERSE used transdermal gel in men and showed noninferiority for major adverse cardiac events (Lincoff et al., 2023). The consensus statement advises against pellet and injectable formulations in women because they produce supraphysiologic concentrations (Davis et al., 2019).
Corrected Evidence-Based Interpretation
The article is correct. TRAVERSE also found more atrial fibrillation, acute kidney injury and pulmonary embolism with testosterone.
Rationale for Grade
The article ranks formulations in a way consistent with the literature, correctly limits TRAVERSE to gel in men and reports the regulatory status of pellets accurately.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"